The Rituxan.com Nurse Center provides helpful resources and information about Rituxan for RA. To access the Nurse Center features, including a Resource Library, Patient Discussion Guide and Infusion Guide, click on any of the icons below.
Resource Library
The Resource Library features brochures, slide decks and other resources focused on Rituxan and RA, and allows you to create customized resource packets that can be printed out or emailed to colleagues and patients.
Patient Discussion Guide
The Patient Discussion Guide provides information designed to help you prepare your patients for Rituxan therapy. This feature also allows you to create a customized Discussion Guide tailored to your patients' specific needs.
Rituxan Treatment Guide
The Rituxan Treatment Guide provides step-by-step instructions for the administration of Rituxan, and includes a supply list, adverse event information, information about managing severe reactions and a drip-rate table to help you calculate infusion concentrations.
Sign up for updates - Keep up to date on Rituxan Nurse Center material. Click here to sign-up.
INDICATION
Rituxan (Rituximab) in combination with methotrexate is indicated to reduce signs and symptoms and to slow the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.
Important Safety Information
Boxed WARNINGS
Fatal Infusion Reactions: Rituxan administration can result in serious, including fatal infusion reactions. Deaths within 24 hours of RITUXAN infusion have occurred. Approximately 80% of fatal infusion reactions occurred in association with the first infusion.
Tumor Lysis Syndrome (TLS): Acute renal failure requiring dialysis with instances of fatal outcome can occur in the setting of TLS following treatment of non-Hodgkin’s lymphoma (NHL) patients with RITUXAN.
Severe Mucocutaneous Reactions: Severe, including fatal, mucocutaneous reactions, can occur in patients receiving RITUXAN.
Progressive Multifocal Leukoencephalopathy (PML): JC virus infection resulting in PML and death can occur in patients treated with Rituxan.
Please see full prescribing information, including Boxed WARNINGS.
